Description: 2seventy bio, Inc., a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. Its products pipeline includes idecabtagene vicleucel; ide-cel or Abecma and bb21217; and CAR-T cell product candidates for the treatment of multiple myeloma. 2seventy bio, Inc. has a collaboration arrangement with Bristol-Myers Squibb Company. The company was incorporated in 2021 and is headquartered in Cambridge, Massachusetts. 2seventy bio, Inc. operates independently of bluebird bio, Inc. as of November 4, 2021.
Home Page: www.2seventybio.com
TSVT Technical Analysis
60 Binney Street
Cambridge,
MA
02142
United States
Phone:
339 499 9300
Officers
| Name | Title |
|---|---|
| Mr. Nick Leschly | Pres, CEO & Director |
| Mr. William D. Baird III | Chief Financial Officer |
| Ms. Nicola H. Heffron | Chief Operating Officer |
| Ms. Susan Abu-Absi Ph.D. | Chief Technology & Manufacturing Officer |
| Dr. Philip D. Gregory D. Phil., DPHIL | Chief Scientific Officer |
| Ms. Teresa L. Jurgensen J.D. | VP, Gen. Counsel & Corp. Sec. |
| Ms. Kathleen A. Wilkinson | Head of People & Culture |
| Mr. Kevin Chin M.D., M.S. | Head of Clinical Devel. |
| Mr. Steven Shamah Ph.D. | Head of Oncology Research |
| Ms. Jenn Snyder | Head of Corp. Affairs |
Exchange: NASDAQ
Country: US : United States of America
Currency: US Dollar ($)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 1.4431 |
| Price-to-Sales TTM: | 8.24 |
| IPO Date: | 2021-11-03 |
| Fiscal Year End: | December |
| Full Time Employees: | 437 |